The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany
Abstract Objectives To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany. Methods From 16th March until 15th June 2020, IRD patients from private pr...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2021-03, Vol.60 (SI), p.SI51-SI58 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | SI58 |
|---|---|
| container_issue | SI |
| container_start_page | SI51 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 60 |
| creator | Hasseli, R Müller-Ladner, U Keil, F Broll, M Dormann, A Fräbel, C Hermann, W Heinmüller, C -J Hoyer, B F Löffler, F Özden, F Pfeiffer, U Saech, J Schneidereit, T Schlesinger, A Schwarting, A Specker, C Stapfer, G Steinmüller, M Storck-Müller, K Strunk, J Thiele, A Triantafyllias, K Vagedes, D Wassenberg, S Wilden, E Zeglam, S Schmeiser, T |
| description | Abstract
Objectives
To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany.
Methods
From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated.
Results
The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients ( |
| doi_str_mv | 10.1093/rheumatology/keab230 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7989169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keab230</oup_id><sourcerecordid>2500376161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-6e3c8830efce4f0985b21b7b2b021e8d0b8909ed90dcac2473729953a67875c43</originalsourceid><addsrcrecordid>eNqNkUtv1DAUhSMEog_4Bwh5ySYdP_IyC6RqBAWpEhItbC3HvmlMY3uwnVb5cfw3PA9GZcfKln3Od4_uKYo3BF8QzNkqjDBbmfzk75bVPcieMvysOCVVQ0vMGH1-vNPqpDiL8SfGuCase1mcMNbiqiLdafH7dgRk3DDN4BQgP6CUH24uv92Ua_-jpGjy6l77R4e8QxuZDLgU0aNJ484l7TZCWNAhjVFImwgyQtwaMssEJPUIYYdPHhlrZ-et1_O0d1rQRmWnd--RRCr4GFEEtX2QE4pp1gvyDxAQQ9a7NMY8GF1BsNItr4oXg5wivD6c58X3Tx9v15_L669XX9aX16Wq2iaVDTDVdQzDoKAaMO_qnpK-7WmPKYFO477jmIPmWCupaNWylnJeM9m0XVurip0XH_bczdznvCovIchJbIKxMizCSyP-_XFmFHf-QbS846ThGfDuAAj-1wwxCWuigmmSDvwcBa0xZm1DGpKl1V66W0WA4TiGYLFtXjxtXhyaz7a3TyMeTX-rzoLVXuDnzf8h_wCAx8Wf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2500376161</pqid></control><display><type>article</type><title>The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Hasseli, R ; Müller-Ladner, U ; Keil, F ; Broll, M ; Dormann, A ; Fräbel, C ; Hermann, W ; Heinmüller, C -J ; Hoyer, B F ; Löffler, F ; Özden, F ; Pfeiffer, U ; Saech, J ; Schneidereit, T ; Schlesinger, A ; Schwarting, A ; Specker, C ; Stapfer, G ; Steinmüller, M ; Storck-Müller, K ; Strunk, J ; Thiele, A ; Triantafyllias, K ; Vagedes, D ; Wassenberg, S ; Wilden, E ; Zeglam, S ; Schmeiser, T</creator><creatorcontrib>Hasseli, R ; Müller-Ladner, U ; Keil, F ; Broll, M ; Dormann, A ; Fräbel, C ; Hermann, W ; Heinmüller, C -J ; Hoyer, B F ; Löffler, F ; Özden, F ; Pfeiffer, U ; Saech, J ; Schneidereit, T ; Schlesinger, A ; Schwarting, A ; Specker, C ; Stapfer, G ; Steinmüller, M ; Storck-Müller, K ; Strunk, J ; Thiele, A ; Triantafyllias, K ; Vagedes, D ; Wassenberg, S ; Wilden, E ; Zeglam, S ; Schmeiser, T</creatorcontrib><description>Abstract
Objectives
To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany.
Methods
From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated.
Results
The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy.
Conclusion
The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician–patient relationship in times of a crisis.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab230</identifier><identifier>PMID: 33704418</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Original</subject><ispartof>Rheumatology (Oxford, England), 2021-03, Vol.60 (SI), p.SI51-SI58</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-6e3c8830efce4f0985b21b7b2b021e8d0b8909ed90dcac2473729953a67875c43</citedby><cites>FETCH-LOGICAL-c476t-6e3c8830efce4f0985b21b7b2b021e8d0b8909ed90dcac2473729953a67875c43</cites><orcidid>0000-0003-2504-3229 ; 0000-0002-2982-8253</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33704418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasseli, R</creatorcontrib><creatorcontrib>Müller-Ladner, U</creatorcontrib><creatorcontrib>Keil, F</creatorcontrib><creatorcontrib>Broll, M</creatorcontrib><creatorcontrib>Dormann, A</creatorcontrib><creatorcontrib>Fräbel, C</creatorcontrib><creatorcontrib>Hermann, W</creatorcontrib><creatorcontrib>Heinmüller, C -J</creatorcontrib><creatorcontrib>Hoyer, B F</creatorcontrib><creatorcontrib>Löffler, F</creatorcontrib><creatorcontrib>Özden, F</creatorcontrib><creatorcontrib>Pfeiffer, U</creatorcontrib><creatorcontrib>Saech, J</creatorcontrib><creatorcontrib>Schneidereit, T</creatorcontrib><creatorcontrib>Schlesinger, A</creatorcontrib><creatorcontrib>Schwarting, A</creatorcontrib><creatorcontrib>Specker, C</creatorcontrib><creatorcontrib>Stapfer, G</creatorcontrib><creatorcontrib>Steinmüller, M</creatorcontrib><creatorcontrib>Storck-Müller, K</creatorcontrib><creatorcontrib>Strunk, J</creatorcontrib><creatorcontrib>Thiele, A</creatorcontrib><creatorcontrib>Triantafyllias, K</creatorcontrib><creatorcontrib>Vagedes, D</creatorcontrib><creatorcontrib>Wassenberg, S</creatorcontrib><creatorcontrib>Wilden, E</creatorcontrib><creatorcontrib>Zeglam, S</creatorcontrib><creatorcontrib>Schmeiser, T</creatorcontrib><title>The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract
Objectives
To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany.
Methods
From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated.
Results
The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy.
Conclusion
The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician–patient relationship in times of a crisis.</description><subject>Original</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkUtv1DAUhSMEog_4Bwh5ySYdP_IyC6RqBAWpEhItbC3HvmlMY3uwnVb5cfw3PA9GZcfKln3Od4_uKYo3BF8QzNkqjDBbmfzk75bVPcieMvysOCVVQ0vMGH1-vNPqpDiL8SfGuCase1mcMNbiqiLdafH7dgRk3DDN4BQgP6CUH24uv92Ua_-jpGjy6l77R4e8QxuZDLgU0aNJ484l7TZCWNAhjVFImwgyQtwaMssEJPUIYYdPHhlrZ-et1_O0d1rQRmWnd--RRCr4GFEEtX2QE4pp1gvyDxAQQ9a7NMY8GF1BsNItr4oXg5wivD6c58X3Tx9v15_L669XX9aX16Wq2iaVDTDVdQzDoKAaMO_qnpK-7WmPKYFO477jmIPmWCupaNWylnJeM9m0XVurip0XH_bczdznvCovIchJbIKxMizCSyP-_XFmFHf-QbS846ThGfDuAAj-1wwxCWuigmmSDvwcBa0xZm1DGpKl1V66W0WA4TiGYLFtXjxtXhyaz7a3TyMeTX-rzoLVXuDnzf8h_wCAx8Wf</recordid><startdate>20210311</startdate><enddate>20210311</enddate><creator>Hasseli, R</creator><creator>Müller-Ladner, U</creator><creator>Keil, F</creator><creator>Broll, M</creator><creator>Dormann, A</creator><creator>Fräbel, C</creator><creator>Hermann, W</creator><creator>Heinmüller, C -J</creator><creator>Hoyer, B F</creator><creator>Löffler, F</creator><creator>Özden, F</creator><creator>Pfeiffer, U</creator><creator>Saech, J</creator><creator>Schneidereit, T</creator><creator>Schlesinger, A</creator><creator>Schwarting, A</creator><creator>Specker, C</creator><creator>Stapfer, G</creator><creator>Steinmüller, M</creator><creator>Storck-Müller, K</creator><creator>Strunk, J</creator><creator>Thiele, A</creator><creator>Triantafyllias, K</creator><creator>Vagedes, D</creator><creator>Wassenberg, S</creator><creator>Wilden, E</creator><creator>Zeglam, S</creator><creator>Schmeiser, T</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2504-3229</orcidid><orcidid>https://orcid.org/0000-0002-2982-8253</orcidid></search><sort><creationdate>20210311</creationdate><title>The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany</title><author>Hasseli, R ; Müller-Ladner, U ; Keil, F ; Broll, M ; Dormann, A ; Fräbel, C ; Hermann, W ; Heinmüller, C -J ; Hoyer, B F ; Löffler, F ; Özden, F ; Pfeiffer, U ; Saech, J ; Schneidereit, T ; Schlesinger, A ; Schwarting, A ; Specker, C ; Stapfer, G ; Steinmüller, M ; Storck-Müller, K ; Strunk, J ; Thiele, A ; Triantafyllias, K ; Vagedes, D ; Wassenberg, S ; Wilden, E ; Zeglam, S ; Schmeiser, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-6e3c8830efce4f0985b21b7b2b021e8d0b8909ed90dcac2473729953a67875c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasseli, R</creatorcontrib><creatorcontrib>Müller-Ladner, U</creatorcontrib><creatorcontrib>Keil, F</creatorcontrib><creatorcontrib>Broll, M</creatorcontrib><creatorcontrib>Dormann, A</creatorcontrib><creatorcontrib>Fräbel, C</creatorcontrib><creatorcontrib>Hermann, W</creatorcontrib><creatorcontrib>Heinmüller, C -J</creatorcontrib><creatorcontrib>Hoyer, B F</creatorcontrib><creatorcontrib>Löffler, F</creatorcontrib><creatorcontrib>Özden, F</creatorcontrib><creatorcontrib>Pfeiffer, U</creatorcontrib><creatorcontrib>Saech, J</creatorcontrib><creatorcontrib>Schneidereit, T</creatorcontrib><creatorcontrib>Schlesinger, A</creatorcontrib><creatorcontrib>Schwarting, A</creatorcontrib><creatorcontrib>Specker, C</creatorcontrib><creatorcontrib>Stapfer, G</creatorcontrib><creatorcontrib>Steinmüller, M</creatorcontrib><creatorcontrib>Storck-Müller, K</creatorcontrib><creatorcontrib>Strunk, J</creatorcontrib><creatorcontrib>Thiele, A</creatorcontrib><creatorcontrib>Triantafyllias, K</creatorcontrib><creatorcontrib>Vagedes, D</creatorcontrib><creatorcontrib>Wassenberg, S</creatorcontrib><creatorcontrib>Wilden, E</creatorcontrib><creatorcontrib>Zeglam, S</creatorcontrib><creatorcontrib>Schmeiser, T</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasseli, R</au><au>Müller-Ladner, U</au><au>Keil, F</au><au>Broll, M</au><au>Dormann, A</au><au>Fräbel, C</au><au>Hermann, W</au><au>Heinmüller, C -J</au><au>Hoyer, B F</au><au>Löffler, F</au><au>Özden, F</au><au>Pfeiffer, U</au><au>Saech, J</au><au>Schneidereit, T</au><au>Schlesinger, A</au><au>Schwarting, A</au><au>Specker, C</au><au>Stapfer, G</au><au>Steinmüller, M</au><au>Storck-Müller, K</au><au>Strunk, J</au><au>Thiele, A</au><au>Triantafyllias, K</au><au>Vagedes, D</au><au>Wassenberg, S</au><au>Wilden, E</au><au>Zeglam, S</au><au>Schmeiser, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2021-03-11</date><risdate>2021</risdate><volume>60</volume><issue>SI</issue><spage>SI51</spage><epage>SI58</epage><pages>SI51-SI58</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract
Objectives
To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany.
Methods
From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated.
Results
The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy.
Conclusion
The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician–patient relationship in times of a crisis.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33704418</pmid><doi>10.1093/rheumatology/keab230</doi><orcidid>https://orcid.org/0000-0003-2504-3229</orcidid><orcidid>https://orcid.org/0000-0002-2982-8253</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2021-03, Vol.60 (SI), p.SI51-SI58 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7989169 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Original |
| title | The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A37%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20influence%20of%20the%20SARS-CoV-2%20lockdown%20on%20patients%20with%20inflammatory%20rheumatic%20diseases%20on%20their%20adherence%20to%20immunomodulatory%20medication:%20a%20cross%20sectional%20study%20over%203%20months%20in%20Germany&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Hasseli,%20R&rft.date=2021-03-11&rft.volume=60&rft.issue=SI&rft.spage=SI51&rft.epage=SI58&rft.pages=SI51-SI58&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab230&rft_dat=%3Cproquest_pubme%3E2500376161%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2500376161&rft_id=info:pmid/33704418&rft_oup_id=10.1093/rheumatology/keab230&rfr_iscdi=true |